Touchlight Completes Expansion of Large DNA Manufacturing Facility
Demand for DNA from biopharmaceutical companies is increasing exponentially.
Stay updated with breaking news from Jonny Ohlson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Demand for DNA from biopharmaceutical companies is increasing exponentially.
Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames. The expanded state-of-the-art ...
Facility will have capacity that exceeds today's global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and r...
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer's clinical and commercial manufacture of its mRNA vaccines, therapeutics